Brief: United Therapeutics Gets FDA Clearance for uKidney Xenotransplantation Clinical Trial
03/02/2025 12:14
Feb 3 (Reuters) - United Therapeutics Corp UTHR.O :
* UNITED THERAPEUTICS CORPORATION ANNOUNCES FDA CLEARANCE OF
ITS
INVESTIGATIONAL NEW DRUG APPLICATION FOR THE UKIDNEY
XENOTRANSPLANTATION CLINICAL TRIAL
* UNITED THERAPEUTICS CORP - FIRST XENOTRANSPLANT EXPECTED
AROUND
MID-YEAR 2025
Source text: ID:nBw73NtjRa
Further company coverage: UTHR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug